Advertisement

Use of Camptothecins in the Treatment of Leukemia and Related Disorders

  • Benjamin M. F. Mow
  • Scott H. Kaufmann
Chapter
Part of the Cancer Drug Discovery and Development book series (CDD&D)

Abstract

Even though current therapy is capable of inducing remissions in 60–80% of adults with acute leukemia (1,2), the vast majority of patients are not cured (3, 4, 5). This is particularly true for the elderly, who account for the majority of cases of acute myelogenous leukemia (AML) (6,7). Because of unrelated medical problems, as well as a higher incidence of certain resistance mechanisms (e.g., overexpression of the mdr1 multidrug transporter), eradicating AML in these patients has been particularly problematic (8,9). These clinical observations highlight the need for new agents to treat AML.

Keywords

Acute Myeloid Leukemia Clin Oncol Maximum Tolerate Dose Acute Leukemia Acute Myelogenous Leukemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lowenberg B, Downing JR, Burnett A. 1999 Acute myeloid leukemia. N Engl J Med 341:1051–1062.Google Scholar
  2. 2.
    Pui CH, Evans WE. 1998 Acute lymphoblastic leukemia. N Engl J Med 339:605–615.Google Scholar
  3. 3.
    Appelbaum FR, Kopecky KJ. 1997 Long-term survival after chemotherapy for acute myeloid leukemia: the experience of the Southwest Oncology Group. Cancer 80:2199–2204.Google Scholar
  4. 4.
    Bennett JM, Young ML, Andersen JW, et al. 1997 Long-term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group experience. Cancer 80:2205–2209.Google Scholar
  5. 5.
    Bloomfield CD, Lawrence D, Byrd JC, et al. 1998 Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58:4173–4179.Google Scholar
  6. 6.
    Rowe JM. 2000 Treatment of acute myelogenous leukemia in older adults. Leukemia 14:480–487.Google Scholar
  7. 7.
    Stone RM, Mayer RJ. 1993 The approach to the elderly patient with acute myeloid leukemia. Hematol Oncol Clin North Am 7:65–79.Google Scholar
  8. 8.
    Advani R, Saba HI, Tallman MS, et al. 1999 Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood 93:787–795.Google Scholar
  9. 9.
    Hoelzer D, Gokbuget N. 2000 New approaches to acute lymphoblastic leukemia in adults: where do we go? Semin Oncol 27:540–559.Google Scholar
  10. 10.
    Rosenfeld C, List A. 2000 A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies. Leukemia 14:2–8.Google Scholar
  11. 11.
    Bennett JM, Catovsky D, Daniel MT, et al. 1982 Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189–199.Google Scholar
  12. 12.
    Fenaux P, Beuscart R, Lai JL, Jouet JP, Bauters F. 1988 Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases. J Clin Oncol 6:1417–1424.Google Scholar
  13. 13.
    Hoagland HC. 1995 Myelodysplastic (preleukemia) syndromes: the bone marrow factory failure problem. Mayo Clinic Proc 70:673–676.Google Scholar
  14. 14.
    Parker JE, Mufti GJ. 1998 Ineffective haemopoiesis and apoptosis in myelodysplastic syndromes. Br J Haematol 101:220–230.Google Scholar
  15. 15.
    Heaney ML, Golde DW. 1999 Myelodysplasia. N Engl J Med. 340:1649–1660.Google Scholar
  16. 16.
    Dansey R. Myelodysplasia. 2000 Curr Opin Oncol 12:13–21.Google Scholar
  17. 17.
    Kaufmann SH. 1998 Cell death induced by topoisomerase-targeted drugs: more questions than answers. Biochim Biophys Acta 1400:195–211.Google Scholar
  18. 18.
    Wu J, Liu LF. 1997 Processing of topoisomerase I cleavable complexes into DNA damage by transcription. Nucleic Acids Res 25:4181–4186.Google Scholar
  19. 19.
    Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH. 1993 The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85:271–291.Google Scholar
  20. 20.
    Brangi M, Litman T, Ciotti M, et al. 1999 Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res 59:5938–5946.Google Scholar
  21. 21.
    Schellens JH, Maliepaard M, Scheper RJ, et al. 2000 Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications. Ann NY Acad Sci 922:188–194.Google Scholar
  22. 22.
    Erlichman C, Boerner SA, Hallgren CG, et al. 2001 The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Cancer Res 61:739–748.Google Scholar
  23. 23.
    Nitiss JL, Wang JC. 1996 Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA. Mol Pharmacol 50:1095–1102.Google Scholar
  24. 24.
    Li LH, Fraser TJ, Olin EJ, Bhuyan BK. 1972 Action of camptothecin on mammalian cells in culture. Cancer Res 32:2643–2650.Google Scholar
  25. 25.
    Horwitz SB, Horwitz MS. 1973 Effects of camptothecin on the breakage and repair of DNA during the cell cycle. Cancer Res 33:2834–2846.Google Scholar
  26. 26.
    Kaufmann SH. 1989 Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res 49:5870–5878.Google Scholar
  27. 27.
    Del Bino G, Darzynkiewicz Z. 1991 Camptothecin, teniposide, 4′-(9-acridinylamino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin, induced degradation of nuclear DNA in the S phase of HL-60 cells. Cancer Res 51:1165–1169.Google Scholar
  28. 28.
    Kharbanda S, Rubin E, Gunji H, et al. 1991 Camptothecin and its derivatives induce expression of the c-jun protooncogene in human myeloid leukemia cells. Cancer Res 51:6636–6642.Google Scholar
  29. 29.
    Solary E, Bertrand R, Kohn KW, Pommier Y. 1993 Differential induction of apoptosis in undifferentiated and differentiated HL-60 cells by DNA topoisomerase I and II inhibitors. Blood 81:1359–1368.Google Scholar
  30. 30.
    Uckun FM, Stewart CF, Reaman G, et al. 1995 In Vitro and in vivo activity of topotecan against human B-lineage acute lymphoblastic leukemia cells. Blood 85:2817–2828.Google Scholar
  31. 31.
    Gottlieb JA, Guarino AM, Call JB, Oliverio VT, Block JB. 1970 Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rpt 54:461–470.Google Scholar
  32. 32.
    Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. 1972 Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rpt 56:95–101.Google Scholar
  33. 33.
    Gottlieb JA, Luce JK. 1972 Treatment of malignant melanoma with camptothecin (NSC-10088). Cancer Chemother Rpt 56:103–105.Google Scholar
  34. 34.
    Johnson RK, Chitnis MP, Embrey WM, Gregory EB. 1978 In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia. Cancer Treat Rep 62:1535–1547.Google Scholar
  35. 35.
    Johnson RK, Howard WS. 1982 Development and cross-resistance characteristics of a subline of P388 leukemia resistant to 4′-(9-acridinylamino)-methanesulfon-m-anisidide. Eur J Cancer Clin Oncol 18:479–487.Google Scholar
  36. 36.
    Potmesil M. 1994 Camptothecins: from bench research to hospital wards. Cancer Res 54:1431–1439.Google Scholar
  37. 37.
    O’Leary J, Muggia FM. 1998 Camptothecins: a review of their development and schedules of administration. Eur J Cancer 34:1500–1508.Google Scholar
  38. 38.
    D’Arpa P, Beardmore C, Liu LF. 1990 Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res 50:6919–6924.Google Scholar
  39. 39.
    Mauer AM, Fisher V. 1962 Comparison of the proliferative capacity of acute leukaemia cells in bone marrow and blood. Nature 193:1085–1086.Google Scholar
  40. 40.
    Killmann S-A. 1965 Proliferative activity of blast cells in leukemia and myelofibrosis. Acta Med Scan 178:263–280.Google Scholar
  41. 41.
    Mauer AM, Fisher V. 1966 Characteristics of cell proliferation in four patients with untreated acute leukemia. Blood 28:428–445.Google Scholar
  42. 42.
    Kantarjian HM, Beran M, Ellis A, et al. 1993 Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood 81:1146–1151.Google Scholar
  43. 43.
    Rowinsky EK, Adjei AA, Donehower RC, et al. 1994 Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. J Clin Oncol 12:2193–2203.Google Scholar
  44. 44.
    Kaufmann SH, Gore SD, Letendre L, et al. 1996 Factors affecting topotecan sensitivity in human leukemia samples. Ann NY Acad Sci 803:128–142.Google Scholar
  45. 45.
    Furman WL, Baker SD, Pratt CB, Rivera GK, Evans WE, Stewart CF. 1996 Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia. J Clin Oncol 14:1504–1511.Google Scholar
  46. 46.
    Houghton PJ, Cheshire PJ, Hallman JD, et al. 1995 Efficacy of topoisomerase I inhibitors, topotecan, and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 36:393–403.Google Scholar
  47. 47.
    Furman WL, Stewart CF, Kirstein M, et al. 2002 Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a pediatric oncology group study. J Clin Oncol 20:1617–1624.Google Scholar
  48. 48.
    Beran M, O’Brien S, Thomas DA, et al. 2003 Phase I study of oral topotecan in hematological malignancies. Clin Cancer Res 9:4084–4091.Google Scholar
  49. 49.
    Rowinsky EK, Kaufmann SH, Baker S, et al. 1996 A phase I and pharmacologic study of topotecan on a 30 minute infusion daily for five day schedule in patients with refractory acute leukemia. Clin Cancer Res 2:1921–1930.Google Scholar
  50. 50.
    Gore SD, Rowinsky EK, Miller CB, et al. 1998 A phase II “window” study of topotecan in untreated patients with high risk adult acute lymphocytic leukemia. Clin Cancer Res 4:2677–2689.Google Scholar
  51. 51.
    Ettinger DS. 1990 Evaluation of new drugs in untreated patients with small-cell lung cancer: its time has come. J Clin Oncol 8:374–377.Google Scholar
  52. 52.
    Castleberry RP, Cantor AB, Green AA, et al. 1994 Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 12:1616–1620.Google Scholar
  53. 53.
    Kearns CM, Blakley RL, Santana VM, Crom WR. 1994 Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. Cancer Res 54:1235–1239.Google Scholar
  54. 54.
    Harris MB, Cantor AB, Goorin AM, et al. 1995 Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study. Med Pediatr Oncol 24:87–92.Google Scholar
  55. 55.
    Schiller JH, Kim K, Hutson P, et al. 1996 Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. J Clin Oncol 14:2345–2352.Google Scholar
  56. 56.
    Perez-Soler R, Fossella FV, Glisson BS, et al. 1996 Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol 14:503–513.Google Scholar
  57. 57.
    Cortes J, Kantarjian HM. 2000 Promising approaches in acute leukemia. Invest New Drugs 18:57–82.Google Scholar
  58. 58.
    Beran M, Estey E, O’Brien SM, et al. 1998 Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymph 31:521–531.Google Scholar
  59. 59.
    O’Brien S, Kantarjian H, Ellis A, Zwelling L, Estey E, Keating M. 1995 Topotecan in chronic lymphocytic leukemia. Cancer 75:1104–1108.Google Scholar
  60. 60.
    Silber R, Degar B, Costin D, et al. 1994 Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs. Blood 84:3440–3446.Google Scholar
  61. 61.
    Rowinsky EK, Kaufmann SH. 1997 Topotecan in combination chemotherapy. Semin Oncol 24:S11–S26.Google Scholar
  62. 62.
    Gupta RS, Gupta R, Eng B, et al. 1988 Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Res 48:6404–6410.Google Scholar
  63. 63.
    Sugimoto Y, Tsukahara S, Oh-hara T, Liu LF, Tsuruo T. 1990 Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res 50:7962–7965.Google Scholar
  64. 64.
    D’Arpa P, Beardmore C, Liu LF. 1990 Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res 50:6919–6924.Google Scholar
  65. 65.
    Kaufmann SH. 1991 Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res 51:1129–1136.Google Scholar
  66. 66.
    Bertrand R, O’Connor PM, Kerrigan D, Pommier Y. 1992 Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur J Cancer 28A:743–748.Google Scholar
  67. 67.
    Chen S, Gomez SP, McCarley D, Mainwaring MG. 2002 Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment. Cancer Chemother Pharmacol 49:347–355.Google Scholar
  68. 68.
    Johnson RK, McCabe FL, Yu Y. 1992 Combination regimens with topotecan in animal tumor models. Ann Oncol 3:85.Google Scholar
  69. 69.
    Crump M, Lipton J, Hedley D, et al. 1999 Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study. Leukemia 13:343–347.Google Scholar
  70. 70.
    Cooper BW, Donaher E, Lazarus HM, et al. 2003 A phase I and pharmacodynamic study of sequential topotecan and etoposide in patients with relapsed or refractory acute myelogenous and lymphoblastic leukemia. Leuk Res 27:35–44.Google Scholar
  71. 71.
    Nair JS, Kancherla R, Seiter K, Traganos F, Tse-Dinh YC. 2000 Action of topoisomerase targeting drugs on non-Hodgkin’s lymphoma and leukemia. Correlation of clinical and cell culture studies. Ann NY Acad Sci 922:326–329.Google Scholar
  72. 72.
    Cortes J, Kantarjian H, Albitar M, et al. 2003 A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. Cancer 97:1234–1241.Google Scholar
  73. 73.
    Park SJ, Kim DW, Kim HJ, et al. 2000 Topotecan-based combination chemotherapy in patients with transformed chronic myelogenous leukemia and advanced myelodysplastic syndrome. Korean J Intern Med 15:122–126.Google Scholar
  74. 74.
    Mainwaring MG, Rimsza LM, Chen SF, et al. 2002 Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levels. Leuk Lymph 43:989–999.Google Scholar
  75. 75.
    Chabner BA. Cytidine analogues. In: Cancer chemotherapy and biotherapy. Chabner BA, Longo DL, eds. Lippincott-Raven, Pennsylvania, 1996, 213–233.Google Scholar
  76. 76.
    Seiter K, Feldman EJ, Halicka HD, et al. 1997 Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia. J Clin Oncol 15:44–51.Google Scholar
  77. 77.
    Vey N, Kantarjian H, Beran M, et al. 1999 Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study. Invest New Drugs 17:89–95.Google Scholar
  78. 78.
    Pagano L, Mele L, Voso MT, et al. 2001 The association of topotecan and cytarabine in the treatment of secondary or relapsed acute myeloid leukemia. Haematologica 86:440–441.Google Scholar
  79. 79.
    Beran M, Estey E, O’Brien S, et al. 1999 Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol 17:2819–2830.Google Scholar
  80. 80.
    Estey EH, Thall PF, Cortes JE, et al. 2001 Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood 98:3575–3583.Google Scholar
  81. 81.
    Beran M, Shen Y, Kantarjian H, et al. 2001 High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. Cancer 92:1999–2015.Google Scholar
  82. 82.
    Miller CB, O’Reilly S, Sartorius S, et al. 1997 A phase I and pharmacologic study of a combination of cyclophosphamide (CY) and topotecan (TOPO) in patients (Pts) with refractory leukemia. Proc Am Soc Clin Oncol 16:203a.Google Scholar
  83. 83.
    Kaufmann SH, Peereboom D, Buckwalter CA, Svingen PA, Donehower RC, Rowinsky EK. 1996 Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst 88:734–741.Google Scholar
  84. 84.
    Janss AJ, Cnaan A, Zhao H, Shpilsky A, Levow C, Sutton L, et al. 1998 Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents in human brain tumor cell lines. Anticancer Drugs 9:641–652.Google Scholar
  85. 85.
    Murren JR, Anderson S, Fedele J, et al. 1997 Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer. J Clin Oncol 15:148–157.Google Scholar
  86. 86.
    Kaufmann SH, Letendre L, Litzow M, et al. 1998 Phase I study of continuous infusion (CI) topotecan (TPT) and carboplatin (CBDCA) for relapsed or refractory acute leukemia. Proc Am Soc Clin Oncol 17:28a.Google Scholar
  87. 87.
    Cheng MF, Chatterjee S, Berger NA. 1994 Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. Oncol Res 6:269–279.Google Scholar
  88. 88.
    Johnson RK, McCabe FL, Gallagher G. 1992 Comparative efficacy of topotecan, irinotecan, camptothecin and 9-aminocamptothecin in preclinical tumor models. Ann Oncol 3:85.Google Scholar
  89. 89.
    Fukuda M, Nishio K, Kanzawa F, et al. 1996 Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. Cancer Res 56:789–793.Google Scholar
  90. 90.
    Meyers FJ, Welborn J, Lewis JP, Flynn N. 1989 Infusion carboplatin treatment of relapsed and refractory acute leukemia: evidence of efficacy with minimal extramedullary toxicity at intermediate doses. J Clin Oncol 7:173–178.Google Scholar
  91. 91.
    Martinez JA, Martin G, Sanz GF, Sempere A, Jarque I, de la Rubia J. 1991 A phase II clinical trial of carboplatin infusion in high-risk acute nonlymphocytic leukemia. J Clin Oncol 9:39–43.Google Scholar
  92. 92.
    Vogler WR. 1993 High-dose carboplatin in the treatment of hematologic malignancies. Oncology 50(Suppl. 2):42–46.Google Scholar
  93. 93.
    Pierce M, Shore N, Sitarz A, Murphy ML, Louis J, Severo N. 1966 Cyclophosphamide therapy in acute leukemia of childhood. Cooperative study conducted by members of Children’s Cancer Cooperative Group A. Cancer 19:1551–1560.Google Scholar
  94. 94.
    Cortes J, Estey E, Beran M, et al. 2000 Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia. Leuk Lymph 36:479–484.Google Scholar
  95. 95.
    Kantarjian H. New developments in the treatment of acute myeloid leukemia: focus on topotecan. Sem Hematol 36:16–25.Google Scholar
  96. 96.
    Lee ST, Jang JH, Suh HC, Hahn JS, Ko YW, Min YH. 2001 Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome. Am J Hematol 68:237–245.Google Scholar
  97. 97.
    Keating MJ, Estey E, O’Brien S, Kantarjian H, Robertson LE, Plunkett W. 1994 Clinical experience with fludarabine in leukaemia. Drugs 47(Suppl 6):39–49.Google Scholar
  98. 98.
    Visani G, Tosi P, Zinzani PL, et al. 1994 FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of ‘poor risk’ acute myeloid leukemias. Leukemia 8:1842–1846.Google Scholar
  99. 99.
    Leoni F, Ciolli S, Nozzoli C, Santini V, Fanci R, Rossi Ferrini P. 2001 Fludarabine, cytarabine and topotecan (FLAT) as induction therapy for acute myeloid leukemia in the elderly: a preliminary report. Haematologica 86:104.Google Scholar
  100. 100.
    Cortes J, Tsimberidou AM, Alvarez R, et al. 2002 Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. Cancer Chemother Pharmacol 50:497–500.Google Scholar
  101. 101.
    Rowinsky EK, Grochow LB, Hendricks CB, et al. 1992 Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 10:647–656.Google Scholar
  102. 102.
    Rowinsky EK, Grochow LB, Ettinger DS, et al. 1994 Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 54:427–436.Google Scholar
  103. 103.
    Chabot GG. 1997 Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 33:245–259.Google Scholar
  104. 104.
    Taguchi T, Wakui A, Hasegawa K, et al. 1990 Phase I clinical study of CPT-11. Research group of CPT-11. Gan To Kagaku Ryoho 17:115–120.Google Scholar
  105. 105.
    Ohno R, Okada K, Masaoka T, et al. 1990 An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 8:1907–1912.Google Scholar
  106. 106.
    Ota K, Ohno R, Shirakawa S, et al. 1994 Late phase II clinical study of irinotecan hydrochloride (CPT-11) in the treatment of malignant lymphoma and acute leukemia. The CPT-11 Research Group for Hematological Malignancies. Gan To Kagaku Ryoho 21:1047–1055.Google Scholar
  107. 107.
    Tsuda H, Takatsuki K, Ohno R, et al. 1994 Treatment of adult T-cell leukaemialymphoma with irinotecan hydrochloride (CPT-11). CPT-11 Study Group on Hematological Malignancy. Br J Cancer 70:771–774.Google Scholar
  108. 108.
    Ribrag V, Suzan F, Ravoet C, et al. 2003 Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts. Leukemia 17:319–322.Google Scholar
  109. 109.
    Bass AJ, Gockerman JP, Hammett E, et al. 2002 Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma. J Clin Oncol 20:2995–3000.Google Scholar
  110. 110.
    Ross DD, Karp JE, Chen TT, Doyle LA. 2000 Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood 96:365–368.Google Scholar
  111. 111.
    Abbott BL, Colapietro AM, Barnes Y, Marini F, Andreeff M, Sorrentino BP. 2002 Low levels of ABCG2 expression in adult AML blast samples. Blood 100: 4594–4601.Google Scholar
  112. 112.
    Giovanella BC, Stehlin JS, Wall ME, et al. 1989 DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246:1046–1048.Google Scholar
  113. 113.
    Jeha S, Kantarjian H, O’Brien S, Vitek L, Beran M. 1998 Activity of oral and intravenous 9-aminocamptothecin in SCID mice engrafted with human leukemia. Leuk Lymph 32:159–164.Google Scholar
  114. 114.
    Rubin E, Wood V, Bharti A, et al. 1995 A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Clin Cancer Re 1:269–276.Google Scholar
  115. 115.
    Takimoto CH, Dahut W, Marino MT, et al. 1997 Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients. J Clin Oncol 15:1492–1501.Google Scholar
  116. 116.
    Eder JP, Rubin E, Stone R, et al. 1996 Trials of 9-amino-20(S)-camptothecin in Boston. Ann NY Acad Sci 803:247–255.Google Scholar
  117. 117.
    Vey N, Kantarjian H, Tran H, et al. 1999 Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia. Ann Oncol 10:577–583.Google Scholar
  118. 118.
    Vey N, Giles FJ, Kantarjian H, Smith TL, Beran M, Jeha S. 2000 The topoisomerase I inhibitor DX-8951f is active in a severe combined immunodeficient mouse model of human acute myelogenous leukemia. Clin Cancer Res 6:731–736.Google Scholar
  119. 119.
    Giles FJ, Cortes JE, Thomas DA, et al. 2002 Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia. Clin Cancer Res 8:2134–2141.Google Scholar
  120. 120.
    Burris HA. 1999 The evolving role of oral topotecan. Semin Hematol 36:26–32.Google Scholar
  121. 121.
    de Jonge MJ, Loos WJ, Gelderblom H, et al. 2000 Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects. J Clin Oncol 18:2104–2115.Google Scholar
  122. 122.
    Gerrits CJ, Schellens JH, Burris H, et al. 1999 A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin). Clin Cancer Res 5:69–75.Google Scholar
  123. 123.
    Masuda N, Fukuoka M, Takada M, et al. 1992 CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 10:1775–1780.Google Scholar
  124. 124.
    Kudoh S, Fujiwara Y, Takada Y, et al. 1998 Phase II Study of Irinotecan Combined with Cisplatin in Patients with Previously Untreated Small-Cell Lung Cancer. West Japan Lung Cancer Group. J Clin Oncol 16:1068–1074.Google Scholar
  125. 125.
    Reid RJD, Fiorani P, Sugawara M, Bjornsti M-A. 1999 CDC45 and DPB11 are required for processive DNA replication and resistance to DNA topoisomerase I-mediated DNA damage. Proc Natl Acad Sci USA 96:11440–11445.Google Scholar
  126. 126.
    Chaturvedi P, Eng WK, Zhu Y, et al. 1999 Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene 18:4047–4054.Google Scholar
  127. 127.
    Cliby WA, Lewis KA, Lilly KK, Kaufmann SH. 2002 S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function. J Biol Chem 277:1599–1606.Google Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2005

Authors and Affiliations

  • Benjamin M. F. Mow
    • 1
  • Scott H. Kaufmann
    • 2
    • 3
  1. 1.Department of Hematology/OncologyNational University HospitalSingapore
  2. 2.Division of Hematology, Department of Internal MedicineMayo ClinicRochester
  3. 3.Division of Hematology, Department of OncologyMayo ClinicRochester

Personalised recommendations